IPIMEDIUM SIGNALFINANCIAL10-K

IPI delivered substantially higher gross profitability while experiencing reduced operating cash flow generation and increased working capital requirements.

The company appears to be in a period of business expansion with meaningfully improved margins, but investors should monitor the disconnect between higher gross profits and lower cash generation. The notable increase in accounts receivable and current liabilities suggests growing business activity but also higher working capital intensity.

Comparing 2026-03-05 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

IPI's financial profile shows mixed signals with gross profit growing substantially while operating cash flow declined by 23%. The balance sheet reflects business expansion with current assets up 28% and notably higher accounts receivable, indicating increased sales activity. However, the reduction in operating cash flow despite improved profitability suggests timing differences or working capital build that merits attention.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
+88.5%
$29.1M$54.8M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Accounts Receivable
Balance Sheet
+50.3%
$22.5M$33.8M

Receivables surged 50.3% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Liabilities
Balance Sheet
+41.2%
$38.0M$53.7M

Current liabilities surged 41.2% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
+28%
$183.8M$235.1M

Current assets grew 28% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
-23.1%
$72.5M$55.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Capital Expenditure
Cash Flow
-21.9%
$38.7M$30.2M

Capex reduced 21.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
+17.2%
$120.1M$140.8M

Liabilities increased 17.2% — monitor debt-to-equity ratio and interest coverage.

SG&A Expense
P&L
+11.3%
$33.0M$36.7M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-04
ADDED
Cash generated from operations is held at the parent company level as cash on hand and short- and long-term investments.
Cash and cash equivalents totaled $83.5 million and $41.3 million at December 31, 2025, and 2024, respectively.
In the event that one or more of our wholly-owned operating subsidiaries guarantee public debt securities in the future, those guarantees will be full and unconditional and will constitute the joint and several obligations of the subsidiary guarantors.
There are no restrictions on our ability to obtain cash dividends or other distributions of funds from the subsidiary guarantors, except those imposed by applicable law.
As of February 28, 2026, the registrant had 13,406,913 shares of common stock, par value $0.001, outstanding.
+7 more — sign up free →
REMOVED
As of February 28, 2025, the registrant had 13,226,281 shares of common stock, par value $0.001, outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 54 Item 7A.
During 2024, we supplied approximately 0.5% of global annual potassium consumption and approximately 3.5% of the U.S.'s annual potassium consumption.
We continue to work to expand sales of byproducts, particularly to serve the oil and gas markets near our operating facilities.
Production Facilities We produce potash from three solar evaporation solution mining facilities: our HB solution mine in Carlsbad, New Mexico, our solution mine in Moab, Utah, and our brine recovery mine in Wendover, Utah.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →